International Paper Company Stock News

In today's jittery market, investors find it increasingly difficult to identify strong buy stocks. Each of these are coming off good earnings.

When a stock breaks out above the 20-day simple moving average, good things could be on the horizon. How should investors react?

When a stock breaks out above the 20-day simple moving average, good things could be on the horizon. How should investors react?

International Paper Co (NYSE:IP ) Q1 2022 Earnings Conference Call April 28, 2022 10:00 AM ET Company Participants Guillermo Gutierrez - VP, IR Mark Sutton - Chairman & CEO Timothy Nicholls - SVP & CF

International Paper's (IP) Q1 results reflect benefits from higher demand. The ongoing momentum in demand is expected to aid results in 2022.

International Paper (IP) delivered earnings and revenue surprises of 46.15% and 4.85%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

International Paper (IP) delivered earnings and revenue surprises of 46.15% and 4.85%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

International Paper's (IP) Q1 performance is likely to reflect solid demand for packaging and pulp products. High costs and the impact of the maintenance outage might have dented some of these gains.

International Paper's (IP) Q1 performance is likely to reflect solid demand for packaging and pulp products. High costs and the impact of the maintenance outage might have dented some of these gains.

International Paper (IP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Ilim Group review and how it will affect IP earnings.

This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice. Little in biotech is working or controlling the pandemic for that matter, but the Biden Administrations Test-to-Treat initiative, announced at the State of the Union, places Todos Medical (OTCMKTS: TOMDF) in the pole position to capitalize on any iteration of pandemic going forward. TOMDF could even leapfrog big pharma giant Pfizer (NYSE: PFE ) which indicated its 3CL protease inhibitor Paxlovid was facing production constraints and is only expected to deliver 3.25 million doses in September. CEO of TOMDF Gerald Commissiong indicated in a Benzinga interview that there is “equivalent clinical activity between our compound and Pfizer’s“ and with respect to sales “it starts with a B not an M.” The company is almost totally derisked and assured a profitable path forward in testing or with the huge upside associated with a drug approval. The current market cap is $27 million and its trading pennies to the dollar.

International Paper (IP) considers the sale of its 50% stake in Ilim JV in Russia over the Ukraine invasion.

International Paper (IP) considers the sale of its 50% stake in Ilim JV in Russia over the Ukraine invasion.